Neidio i’r brif dudalen lywio Neidio i chwilio Neidio i’r prif gynnwys

Development of a diagnostic compatible BCG vaccine against Bovine tuberculosis

  • Aneesh Chandran
  • , Kerstin Williams
  • , Tom Mendum
  • , Graham Stewart
  • , Simon Clark
  • , Sirine Zadi
  • , Neil McLeod
  • , Ann Williams
  • , Bernardo Villarreal-Ramos
  • , Martin Vordermeier
  • , Veerasamy Maroudam
  • , Aravind Prasad
  • , Neeraj Bharti
  • , Ruma Banerjee
  • , Sunitha Manjari Kasibhatla
  • , Johnjoe McFadden*
  • *Awdur cyfatebol y gwaith hwn
  • University of Surrey
  • Public Health England
  • Animal and Plant Health Agency
  • Translational Research Platform for Veterinary Biologicals (India)
  • Centre for Development of Advanced Computing

Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

19 Dyfyniadau (Scopus)
96 Wedi eu Llwytho i Lawr (Pure)

Crynodeb

Bovine tuberculosis (BTB) caused by Mycobacterium bovis remains a major problem in both the developed and developing countries. Control of BTB in the UK is carried out by test and slaughter of infected animals, based primarily on the tuberculin skin test (PPD). Vaccination with the attenuated strain of the M. bovis pathogen, BCG, is not used to control bovine tuberculosis in cattle at present, due to its variable efficacy and because it interferes with the PPD test. Diagnostic tests capable of Differentiating Infected from Vaccinated Animals (DIVA) have been developed that detect immune responses to M. bovis antigens absent in BCG; but these are too expensive and insufficiently sensitive to be used for BTB control worldwide. To address these problems we aimed to generate a synergistic vaccine and diagnostic approach that would permit the vaccination of cattle without interfering with the conventional PPD-based surveillance. The approach was to widen the pool of M. bovis antigens that could be used as DIVA targets, by identifying antigenic proteins that could be deleted from BCG without affecting the persistence and protective efficacy of the vaccine in cattle. Using transposon mutagenesis we identified genes that were essential and those that were non-essential for persistence in bovine lymph nodes. We then inactivated selected immunogenic, but non-essential genes in BCG Danish to create a diagnostic-compatible triple knock-out ΔBCG TK strain. The protective efficacy of the ΔBCG TK was tested in guinea pigs experimentally infected with M. bovis by aerosol and found to be equivalent to wild-type BCG. A complementary diagnostic skin test was developed with the antigenic proteins encoded by the deleted genes which did not cross-react in vaccinated or in uninfected guinea pigs. This study demonstrates the functionality of a new and improved BCG strain which retains its protective efficacy but is diagnostically compatible with a novel DIVA skin test that could be implemented in control programmes.

Iaith wreiddiolSaesneg
Rhif yr erthygl17791
Nifer y tudalennau11
CyfnodolynScientific Reports
Cyfrol9
Rhif cyhoeddi1
Dyddiad ar-lein cynnar28 Tach 2019
Dynodwyr Gwrthrych Digidol (DOIs)
StatwsCyhoeddwyd - 28 Tach 2019

NDC y CU

Mae’r allbwn hwn yn cyfrannu at y Nod(au) Datblygu Cynaliadwy canlynol

  1. NDC 3 - Iechyd a Llesiant Da
    NDC 3 Iechyd a Llesiant Da

Ôl bys

Gweld gwybodaeth am bynciau ymchwil 'Development of a diagnostic compatible BCG vaccine against Bovine tuberculosis'. Gyda’i gilydd, maen nhw’n ffurfio ôl bys unigryw.

Dyfynnu hyn